Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) revealed on Wednesday that the US Food and Drug Administration (FDA) has issued a Complete Response Letter relating to the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.
The FDA requested additional information concerning the manufacturing process and the type 1 diabetes indication.
Novo Nordisk said that it will work closely with the FDA to address the requests but does not expect to be able to do so in 2024.
Insulin icodec is approved for both type 1 and type 2 diabetes in the European Union, Canada, Australia, Japan and Switzerland, and for type 2 diabetes in China.
Scopio Labs secures fourth FDA clearance
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
Alvotech strengthens biosimilar operations with acquisition of Ivers-Lee Group
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Life Molecular Imaging's Neuraceq granted expanded Alzheimer's disease indications by US FDA